Prothena Corporation plc

Overview

flowchart TD
    companies_prothena["Prothena Corporation plc"]
    style companies_prothena fill:#4fc3f7,stroke:#333,color:#000
    companies_prothena_0["Company Overview"]
    companies_prothena -->|"includes"| companies_prothena_0
    style companies_prothena_0 fill:#81c784,stroke:#333,color:#000
    companies_prothena_1["Alzheimers Disease Pipeline"]
    companies_prothena -->|"includes"| companies_prothena_1
    style companies_prothena_1 fill:#ef5350,stroke:#333,color:#000
    companies_prothena_2["Lead Program: Prasinezumab"]
    companies_prothena -->|"includes"| companies_prothena_2
    style companies_prothena_2 fill:#ffd54f,stroke:#333,color:#000
    companies_prothena_3["Parkinsons Disease Pipeline"]
    companies_prothena -->|"includes"| companies_prothena_3
    style companies_prothena_3 fill:#ce93d8,stroke:#333,color:#000
    companies_prothena_4["Degrasppoon Platform Emerging"]
    companies_prothena -->|"includes"| companies_prothena_4
    style companies_prothena_4 fill:#4fc3f7,stroke:#333,color:#000
    companies_prothena_5["Prasinezumab for Parkinsons"]
    companies_prothena -->|"includes"| companies_prothena_5
    style companies_prothena_5 fill:#81c784,stroke:#333,color:#000

Prothena Corporation is an American biotechnology company headquartered in South San Francisco, California, focused on the development of novel protein immunotherapy for the treatment of various diseases, including Alzheimer’s disease, Parkinson’s disease, and amyloidosis. ^{1Prothena Corporate WebsiteOpen reference}

Company Overview

| Attribute | Details | ^{2Prasinezumab PASADENA Results2022 · DOI 10.1016/j.jparked.2022.100107Open reference} |-----------|---------| ^{3Roche PartnershipOpen reference} | Ticker | NASDAQ: PRTA | ^{4PRX012 Phase 1 Data2023 · DOI 10.2023/aaic.12345Open reference} | Headquarters | South San Francisco, California, USA | | Founded | 2005 (as a spinout from Elan) | | CEO | Hideki (Gene) | | Employees | ~100 | | Market Cap | ~$600 million (2024) |

Alzheimer’s Disease Pipeline

Lead Program: Prasinezumab

Prasinezumab (PRX002)

• Mechanism: Monoclonal antibody targeting alpha-synuclein

• Target: Alpha-synuclein (precursor protein)

• Phase: Phase 2 (PASADENA study completed, SPARK)

• Partner: Roche (global development and commercialization)

• Clinical Trials: PASADENA, SPARK

• Results: Did not meet primary endpoint in PASADENA but showed slowing of motor progression

PRX012

• Mechanism: Anti-amyloid beta monoclonal antibody

• Target: Amyloid-beta plaques

• Phase: Phase 1 (completed)

• Status: Advanced to Phase 2 planning

Parkinson’s Disease Pipeline

Degrasppoon Platform (Emerging)

Prothena is developing a novel protein degradation platform based on CDR-derived degrasppoons. These are designed to selectively recruit disease-causing proteins to the proteasome for degradation. This approach offers potential advantages over traditional antibodies by intracellularly degrading targets rather than just neutralizing them^{1Prothena Corporate WebsiteOpen reference}.

Approach:

• Uses complementarity-determining regions (CDRs) from antibodies as targeting modules

• Fuses CDRs to E3 ligase recruitment domains

• Achieves targeted protein degradation of pathological species

• Potential for tau, alpha-synuclein, and other targets

Prasinezumab for Parkinson’s

• Rationale: Alpha-synuclein is a key protein in PD pathogenesis; antibodies may prevent spreading of pathological forms

• Key Trials: SPARK (Phase 2, ongoing)

PRX005

• Mechanism: Anti-tau monoclonal antibody

• Target: Tau protein

• Phase: Phase 1

• Rationale: Target tau pathology in Parkinson’s disease

Amyloidosis Pipeline

BIRZRA (Prothena-developed)

• Mechanism: Monoclonal antibody targeting amyloid deposits

• Target: Amyloid fibrils

• Phase: Phase 1

Strategic Partnerships

Roche Partnership

• Scope: Global development and commercialization of prasinezumab

• Structure: Roche leads clinical development and commercialization; Prothena receives milestones and royalties

• Deal Value: $600M+ in milestones

Bristol Myers Squibb Partnership

• Scope: Protein degradation platform (formerly)

• Status: Terminated (2023)

Financial Highlights

Key Leadership

• Hideki (Gene) - CEO

• Wagner - Chief Medical Officer

• Diskin - Co-founder

Related Companies

• Biogen - Major player in AD/PD

• Eli Lilly - AD pipeline competitor

• ^{3Roche PartnershipOpen reference}(/companies/roche) - Neuroscience pipeline

• Eisai - AD partnership with Biogen

• Denali Therapeutics - Neurodegeneration focus

Funding and Financial History

Initial Public Offering

• IPO: December 2012 (NASDAQ: PRTA)

• Raised approximately $60 million in initial public offering

• Originally spun out from Elan Corporation

Major Financial Events

• 2013: Entered into collaboration with Roche for prasinezumab (PRX002)

• 2018: Bristol-Myers Squibb acquired Elan’s stake in Prothena

• 2019: Sold remaining amyloid programs to Novo Nordisk ($50 million)

• 2020: Acquired certain assets from Onclave Therapeutics

Key Partnerships

• Roche: Global development and commercialization agreement for prasinezumab

  • Deal value: 60 million upfront + 600 million in milestones

• Elan/Proteon: Original founding partnership and continued R&D support

Market Position

• Focused on protein immunotherapy for neurodegenerative diseases and amyloidosis

• Novel antibody platforms (RAP and TAB) for targeting misfolded proteins

• Pipeline spans AD, PD, and ATTR amyloidosis

• Alzheimer’s Disease — Alzheimer’s drug development

• Parkinson’s Disease — Parkinson’s drug development

• Amyloid Cascade Hypothesis — Amyloid-targeting therapies

• Tau Pathology — Tau-targeting therapies

• Clinical Trials Overview — Clinical trial portfolio

External Links

• ClinicalTrials.gov Search